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ABSTRACT 
Purpose: To identify factors affecting the concentration loss during the 
manufacturing process of Beta Domain Deleted Recombinant Human Factor VIII 
(BDDrFVIII SQ) 
Methods: Lyophilization cycles were stopped after each stage to characterize the 
protein through the cycle. Three different types of glass tubing vials; untreated, 
silicon dioxide coated, and siliconized were evaluated. Two fonnulations of 
BDDrFVIII SQ were evaluated to detennine the effects of a concentrated formula. 
Factor VIII concentration (µg /ml) was determined using an anion exchange high 
performance liquid chromatography (HPLC) assay, with ultraviolet (UV) and 
fluorescence detection. 
Results: The freezing and annealing stages were found be critical aspects of the 
lyophilization cycle. Comparison of the three types of glass vials demonstrated that 
treated vials (siliconized or silicon dioxide) yielded greater protein concentrations. 
The formulation experiment indicated that a concentrated formula (2X) is superior to 
the standard formulation for protein recovery. 
Conclusions: The current freezing cycle produces an ice crystal structure that 
damages the protein and may increase susceptibility to denaturation and aggregation 
upon reconstitution. Treated vials showed a significant benefit over untreated glass 
vials in the recovery of protein, but did not ameliorate the problem entirely. This 
indicates that the protein loss is only partially due to protein-surface interactions 
resulting in adsorption. Through fortification of the fonnula and decreasing the 
amount of water, there is less protein lost during lyophilization and reconstitution 
ACKNOWLEDGEMENTS 
The research for my Master's degree has provided a valuable learning 
opportunity in a "real world" setting. The opportunity to assess, plan, perform, and 
interpret has encouraged the development of my professional skills as a researcher. I 
would have not been able to accomplish this task without the tremendous support and 
encouragement from many gifted scientists. I would like to thank my major advisor 
Dr. Thomas Needham for his guidance and encouragement to pursue this joint Doctor 
of Pharmacy and Master's of Phamiacuetics for his flexibility and support of all my 
academic goals. 
I thank the talented scientist at Wyeth BioPharma for providing laboratory and 
scientific support for this project. I thank Dr. Kasra Kasraian and Edie Neidhardt of 
Wyeth BioPharma for their hands on approach to data analysis, experimental 
planning and execution. I thank my colleagues and friends Donovan Quinn and 
Christian Ruitberg for their expertise in manufacturing and lyophilization. 
I would like to thank the University of Rhode Island College of Pharmacy and 
would not have lasted seven years at this university without the help of a talented and 
supportive faculty and staff. I thank Dr. John Babson for his encouragement to "rock 
the boat every now and then" and his jocularity. I sincerely thank Dean Lausier, 
Dean Letendre, and Dr. Chichester the department chair, for their unwavering support 
during my time at this university. 
This list would not be complete without a special thanks to my family, who 
has indoctrinated the values of perseverance, and hard work. Their support both 
fiduciary and emotional has turned my goals into achievements throughout my life. 
lll 
TABLE OF CONTENTS 
ABSTRACT ................................................................................... .ii 
ACKNOWLEDGEMENTS ................................................................. iii 
TABLE OF CONTENTS ................................................................... .iv 
LIST OF TABLES ............................................................................ v 
LIST OF FIGURES .......................................................................... vi 
BACKGROUND .............................................................................. 1 
STATEMENT OF THE PROBLEM ..................................................... 24 
MATERIALS ................................................................................. 25 
METHODS .................................................................................... 27 
RESULTS AND DISCUSSION ............................................................ 35 
STUDY LIMITATIONS .................................................................... 49 
CONCLUSIONS AND FUTURE WORK .............................................. 50 
REFERENCES ............................................................................... 52 
APPENDICES ................................................................................ 56 
BIBLIOGRAPHY ........................................................................... 78 
lV 
LIST OFT ABLES 
Table 1: Lyophilization cycle with annealing ........................................ ..... .. 28 
Table 2: Lyophilization cycle without annealing .... . ....... .... ..... ......... .... ... ..... . 29 
Table 3: Freeze/Hold Study- Diluted with 0.9% NaCl.. .................................. 39 
Table 4: Protein Recovery as a percentage between lyophilization cycles that anneal 
and do not. .......................... ... .. ... .......... .. .... .. ... ...... ....... . ................ .. 41 
Table 5: Comparison of the recovery of protein as a percentage of the initial frozen 
polypropylene concentration ................................................................. .4 7 
v 
LIST OF FIGURES 
Figure 1: The four structures of protein ................. ... .......... .. ........ .............. 2 
Figure 2: Blood clotting cascade ................. ...... ....................................... .4 
Figure 3: Deamidation reaction of asparagine ...................................... .. ....... 8 
Figure 4: Methionine oxidation reaction ...................................................... 9 
Figure 5: Diagram of two potential reactions: A) Normal protein folding. 
B) Aggregation of protein ..................................................................... 10 
Figure 6: An overview of stage 2 of the aseptic manufacturing process ......... . ...... 13 
Figure 7: Product temperature versus shelf temperature in the stages of a 
standard lyophilization cycle without an annealing step ............................ .. .... 16 
Figure 8: The structure of the B-domain deleted factor Vill ............. . ............. .. .22 
Figure 9: Schematic diagram of physical and chemical transformations affecting 
r-Vill SQ ........... .. ....................................... . .. ... .... ........................... 23 
Figure 10: Full lyophilization cycle with annealing ....................................... 28 
Figure 11: Lyophilization Startup: Comparison between annealing and 
not annealing ................ . ................................................................... 29 
Figure 12: COBAS-FARA (2 Step Kinetic Chromogenic Bioassay)- Step 1 .... .... .. 31 
Figure 13: COBAS-FARA (2 Step Kinetic Chromogenic Bioassay)- Step 2 .......... 31 
Figure 14: Sample of Factor Vill HPLC Chromatogram .......... ... ...... .............. 33 
Figure 15. An explanation of means one-way ANOVA diamonds and 
x-Axis proportional model. ...... .. ............................... .... ........... . ............ 34 
Figure 16: Protein concentration recovery as a percentage for each step 
of the lyophilization cycle . . .... .. .................. .............. .... ..... .. ........... .. . .... 36 
Vl 
Figure 17: Concentration (µg/mL) results for the Freeze/Hold study without 
dilution ....... . .... . ....................... . .. . ... . . ....... ................ ... ... . ...... ......... 38 
Figure 18: Concentration (µg/mL) of lyophilized products with or without an 
annealing step after reconstitution ....................................... . ........ . ..... .. .. .41 
Figure 19: Siliconized vs. untreated vials- Concentration (µg/mL) by 
Mono Q HPLC ................................................................................. 43 
Figure 20: Siliconized vs. Untreated Vials- Potency(U/mL) by COBAS-F ARA . .. .43 
Figure 21: Mean Concentration (µg/mL) of untreated vials vs. 
silicon dioxide ( 1 +) vials . ...... ................ .. .. . .... . .... . ...................... .. ....... .44 
Figure 22- Recovery of protein (µg/mL) when comparing lX and 2X 
formulations in both coated and untreated vials .......................................... .46 
Vll 
Background 
The Food and Drug Administration (FDA) defines biologics as, "any virus, 
therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, 
allergenic product or analogous product, or arsphenamine (arsenic compound), or its 
derivatives, applicable to the prevention, treatment, or cure of disease or injuries of 
man."1 Protein drugs are classified as biologics and are increasingly used for a broad 
range of indications from arthritis to cancer. Biologics have a high degree of 
specificity for receptor targets, yielding greater efficacy and lower side effect profiles. 
Protein drugs are one of the fastest growing sectors within the pharmaceutical 
industry with nearly $33 billion dollars in worldwide sales in 2002.2 Development of 
protein drugs represents new avenues of therapy with hundreds of drugs either in the 
pipeline or on the market. The development of biological products has been 
considered a challenge because of the protein's complex structural nature and the 
propensity for chemical and physical reactivity. 
In order to understand the complexity of proteins, the structural characteristics 
must first be described. Proteins are composed from the covalent bonding of some or 
all of the twenty basic amino acids3, as seen in Figure 1 a. The primary structure of a 
protein contains at least 50 amino acids, while structures are classified as 
polypeptides if they contain less than 50 amino acids.4 The secondary structure 
consists of local conformations of the polypeptide chains, and folding of the proteins 
into alpha helices, beta strands and beta turns, Figure 1 b. Tertiary structures are 
three-dimensional polypeptide chains, comprised of domains (specific functional 
units), which form a functional protein under physiologic conditions, Figure le. 
1 
Quaternary structures are the assembly of large individual polypeptide chains in large 
multi subunit proteins,3 Figure ld. A simplified overview of protein structures can 
be seen in Figure 1. 
Figure 1. The four structures of protein5 
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Complex protein structures result in higher molecular weights than found in 
conventional drugs, and an increased chance of destabilizing reactions. Protein 
stability is dependent on multiple factors, including: proper folding, covalent 
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(disulfide) bonding and non-covalent (Hydrogen, ionic, Van der Waals, and 
hydrophobic) bonding.6 In a drug, instability can cause: loss of active potency, 
altered pharmacokinetics, loss of content uniformity, loss of pharmaceutical elegance, 
and the formation of toxic degradation products. 7 According to the FDA, sec 211.166 
"There shall be a written testing program designed to assess the stability 
characteristics of drug products. The results of such stability testing shall be used in 
determining appropriate storage conditions and expiration dates ."8 Therefore, to 
maximize a drug's shelf life, a complex product must be effectively stabilized when 
formulated and manufactured. 
Hemophilia 
Hemophilia is a hereditary blood disease marked by prolonged coagulation 
time, yielding a failure of the blood to clot and abnormal bleeding.9 Hemophilia A, 
which is called classical hemophilia is caused by a deficiency of factor YID (FVID); 
Hemophilia B, known as The Christmas disease is caused by a deficiency of factor 
IX. 10 This thesis will address only Hemophilia A and therapies associated with 
treatment of this disorder. The gene for FVID is a 186-kilo base (kb) of the X 
chromosome and comprised of 26 exons and 25 introns, with mature FVID protein 
consisting of 2332 amino acids. 11 Exons are DNA sequences that code information 
for protein synthesis, while introns are DNA sequences between exons which are 
removed and do not function in the synthesis of protein. 12 
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Factor VIII 
FVID is a homologous protein, which circulates in the plasma and is bound to 
the transporter protein, von Willebrand Factor (vWF), until FVID is cleaved by 
thrombin to yield activated factor Vill (FVilla). 13 As well as acting as a transporter 
protein, vWF is involved in primary hemostasis by promoting adhesion of platelets to 
the sub endothelium, resulting in a plug formation at sites of vascular injury. 14 
FVilla has no independent enzymatic activity, but acts as a cofactor to increase the 
proteolytic efficiency of factor IXa. 13 These factors are essential for successful 
completion of the coagulation cascade and the formation of a blood clot, seen below 
in Figure 2. 
Figure 2. Blood clotting cascade15 
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Factor VIII Products 
Concentrates ofFVIII derived from human plasma have been in use since the 
1960's.16 Plasma derived FVIII ranges from l 70Kd - 280Kd depending on the active 
form of FVIII employed. 17 FVIII is found only in trace amounts (0.11 mg/L) in 
human plasma, and between 1500 Kg and 5000 Kg of human plasma is processed and 
enriched, to provide a yield of 18-22% of concentrated FVIII-VWF. 14 The plasma 
used in the manufacturing ofFVIII is extracted from donated human blood and must 
be viewed as a finite resource. 
Prior to 1983, more than half of the hemophiliacs treated with plasma derived 
FVIII were infected with HIV. 11 New technology and standards have been developed 
over the past twenty years to decrease the transmission of viruses through therapeutic 
products. Current FVIII products (plasma-derived and recombinant) are considered 
safe due to viral inactivation and removal steps in the manufacturing process, which 
can reduce viral load by several orders of magnitude. 18 No FVIII products have 
transmitted HIV, hepatitis B or hepatitis C since 1987. 19 Second only to viral 
infection, FVIII inhibitor development has been the most serious complication 
associated with plasma derived hemophilia treatment. Inhibitors are antibodies that 
react with FVIII to hinder the pro-coagulant function, and may present in varying 
severity in approximately 20% of severe hemophiliacs.20 
Concerns over inhibition fonnation, limited access to plasma, and potential 
viral transmissions led to the development ofrecombinant FVIII products. 16 The first 
recombinant antihemophilic factor was approved in 1992, but contained blood-
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derived additives from humans or animals, most notably albumin.19 Recombinant 
FVill is synthesized by a genetically engineered Chinese Hamster Ovary (CHO) cell 
line, then purified with a series of chromatography columns, before viral inactivation 
with a solvent-detergent treatment step (product dependent). 21 Recombinant FVIII 
products may require albumin or other macromolecular stabilizers. 17 In 2003 , 
Advate®, a recombinant factor VIII free of additives derived from human or animal 
sources was approved and provided added reassurance against risk of infection. 19 This 
thesis will discuss issues associated with another albumin and plasma free product 
currently in development, namely the beta domain deleted recombinant factor VIII 
(BDDrFVIII SQ). 
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Degradation Pathways for proteins 
Chemical 
Deamidation and oxidation are two important reactions that may cause 
chemical instability. Deamidation results in spontaneous non-enzymatic degradation 
and loss of amino acid sequence homogeneity, commonly affecting asparagine, which 
is changed to aspartate or isoaspartate. 22 The mechanism of the intra molecular 
reaction occurs when an amide side chain is attacked by a succinirnide ring 
intermediate,23 Figure 3 reaction A. In a basic environment, the succinimide ring is 
hydrolyzed into either an aspartyl residue or an isoaspartyl residue, Figure 3 reaction 
B.24 This inverts the charge of the amino acid from positive to negative, and increases 
susceptibility to protease activity and denaturation yielding a decrease in the protein's 
activity.25 Detection systems monitor charge, molecular weight changes and a direct 
measurement of succinimide or isoaspartic residue formation. 26 Lowering the pH of a 
protein formulation decreases the occurrence of succinimide deamidation, but also 
increases the chance for hydrolysis deamidation.23 In Figure 3, reaction A is the 
primary degradation step to the intermediate, and reaction B completes the reaction to 
the two possible products. 22 
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Figure 3. Deamidation reaction of asparagine 
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Oxidation is the covalent modification of a protein induced by reactive 
oxygen intermediates or by-products of oxidative stress.27 Oxidation may occur in a 
number of amino acids, but is most commonly seen in cysteine and methionine (see 
Figure 4.28 ). Oxidation results from exposure to air, intense fluorescent light, and/or 
residual peroxide content. 7 Oxidation may have varying effects on amino acids, but 
the formation of free radicals is considered the most dangerous. Free radicals are 
unstable and highly reactive molecules associated with cellular tissue damage, and are 
believed to accelerate the progression of serious disease states. 12 Antioxidants are 
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added while pH, and temperature adjustments are made to decrease oxidative product 
build up .28 Antioxidants act as free radical scavengers and oxygen acceptors to 
minimize damage to the protein.27 Oxidation occurs optimally at neutral or basic pH 
and decreasing the pH can diminish aggregation or disulfide scrambling.7 
Physical 
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Figure 4. Methionine oxidation reaction.29 
Physical Instabilities, such as aggregation/precipitation and surface adsorption, 
comprise another major destabilizing factors for protein drug formulations. 28 
Aggregation is the most prevalent means by which a physical instability in protein 
structure is manifested.30 Aggregation is a microscopic association of protein 
molecules, while precipitation forms visible protein particles that decrease potency 
and alter solution appearance,6 Fig. 5. The aggregation of proteins through subtle 
structural changes is responsible for associative behavior.31 Physical factors 
including temperature, ionic strength, agitation, and surface/interface adsorption, all 
result in an increased hydrophobic surface area, yielding protein aggregation.28 
Protein aggregates may be soluble and create a reversible problem. 30 Precipitation 
may result from protein-salt interactions, yielding a "salting-out" effect when high 
concentrations of salt interact with hydrophobic residues of the protein. 32 
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Figure 5. Diagram of two potential reactions: A) Normal protein folding. B) 
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Adsorption to containers, equipment, and other surfaces for protein drugs 
present more challenges in production and storage than traditional pharmaceuticals. 
Two mechanisms: hydrophobic interactions accompanied by dehydration and 
electrostatic (charge-charge) interactions between the protein and the surface result in 
adsorption.34 Surface energy has been identified as a major factor influencing protein 
adsorption, with hydrophobic surfaces adsorbing more protein than hydrophilic 
surfaces.35 
Protein administration is parenteral, which requires a sterile environment for 
manufacturing and a sterile dosage form. Filters are used to keep products free from 
contamination but may result in adsorption of proteins through electrostatic 
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interactions.36 Filters vary in their composition materials, yielding varying levels of 
hydrophobicity, reactivity, and extractability into the protein product. 37 Therefore, 
during formulation it is important to assess the protein and filter to ensure avoiding a 
significant amount of adsorption.6 
Once placed in product vials, proteins may adhere to glass surfaces, further 
reducing available drug concentrations in a product. Untreated glass surfaces are 
anionic, and adsorb cationic38 and amphipathic biologics resulting in loss of 
concentration. Initial concentrations of protein drugs are generally low; with a small 
loss resulting in a significant relative loss of active ingredient.39 Surfactants such as 
polysorbates, and pleuronics may greatly reduce adsorption rates to solid surfaces.40 
Another strategy for decreasing protein adsorption is coating pharmaceutical glass 
with silicone or polymers to render the glass surface inert. Glass is dipped or sprayed 
with a solution of silicone or polymer, then cured in an oven under defined time and 
temperature conditions. 41 This coating repels a water layer and decreases the 
adsorption of some proteins, but may inadvertently adsorb other proteins (i .e. albumin, 
IgG, and IgM). 38 
Liquid formulations of protein drugs are the preferred dosage form, from a 
cost and ease of production viewpoint. The addition of excipients (surfactants, 
antioxidants, etc.) to some protein drugs will resolve their instability and create a 
viable liquid dosage form. Drugs that do not respond require a different approach to 
formulation, and manufacturing; lyophilization is often used for these difficult cases. 
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Drug Product Manufacturing 
Manufacturing a protein product is a long and complex process beginning 
with amino acids and ending with a final lyophilized product. The process can be 
divided into two stages: Stage one is the production of a bulk protein substance and 
the freezing of that bulk for shipment and further processing. Stage two, as presented 
in figure 6, consists of thawing the bulk drug substance and processing it into a viable 
drug product for the consumer. This research will address the second stage of protein 
manufacturing and issues associated with this process. 
It is important to understand that the overall manufacturing process must be 
preformed in appropriate environments, in order to minimize the risk of product 
contamination. According to the FDA "Guidance for Industry: Sterile Drug Products 
Produced by Aseptic Processing- Current Good Manufacturing Practice." 
"In an aseptic process, the drug product, container, and closure are first subjected 
to sterilization methods separately, as appropriate, and then brought 
together. Because there is no process to sterilize the product in its final container, 
it is critical that containers be filled and sealed in an extremely high-quality 
environment (Class 100). Before aseptic assembly into a final product, the 
individual parts of the final product are generally subjected to various sterilization 
processes. Any manual or mechanical manipulation of the sterilized drug, 
components, containers, or closures prior to or during aseptic assembly poses the 
risk of contamination and thus necessitates careful control.'"'2 
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Figure 6. An overview of stage 2 of the aseptic manufacturing process. 43 
Thawing Pooling Formulation Filtration 
Lyophilization Capping Inspection 
Thaw 
Drug substance or active pharmaceutical ingredient (API), is defined as the 
unformulated active substance which may be subsequently formulated with exc!pients 
to produce the drug product.44 Pooled lots of bulk drug substance are often frozen in 
vessels for easier storage and shipping. Thawing these vessels may be 
thermodynamically different than simply using the opposite requirements for freezing 
the vessel, and must be carefully evaluated.45 
When drug substance is needed for processing to a final product, the 
containers are thawed under temperatures ranging from refrigerated conditions (2-8 
0 C) to as high as 30 °C.46 During thawing, the liquid phase appears first at the surface 
of heat transfer, then quickly separates the frozen product mass from the heating 
surface. Thawing may be accomplished through externally jacketed vessels, which 
circulate a thermodynamic transfer medium around the outside of the container. 
Internally thawed material is pumped to the top of the frozen mass, around the ice 
mass, and then return to the vessel bottom to increase the melting rate and 
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homogeneity of the substance.45 Thawing is complete when all water molecules are 
released from the ice matrix into the amorphous phase.46 Additional external 
mechanical agitation of the entire vessel yields quicker and more uniform thaws by 
stirring the liquid and solid phases together.45 Mixing during the thaw will minimize 
any freeze-induced active pharmaceutical ingredient concentration effects that may 
. h fr . 46 occurr dunng t e eezmg process. 
Formulation 
The thawed drug substance is then formulated into the drug product. 
Formulation is the ordered addition of the recommended excipients at the appropriate 
concentrations, and the adjustment of protein concentration, pH, and ionic strength.30 
Proper formulation must be developed and validated rigorously to provide a viable 
final product. Physical characterization identifies particle size and distribution, shape, 
surface area, density and porosity of a product.47 Chemical characterization identifies 
product potency, solubility, stability, reactivity, and purity.47 Product characterization 
identifies potential buffer systems, cryoprotectants, lyoprotectants, and/or other 
excipients required in the formulation. 48 The order of addition of excipients may also 
impact product quality, as a result of interim reactions of higher local concentrations 
of excipients than their end concentrations in the mixed formulated bulk. 30 
Filter & Filling 
The formulated drug product must be sterilized to remove microorganisms 
and other harmful materials . Filtration is the preferred method for sterilization of 
14 
expensive and heat-sensitive proteins.49 Filters physically remove microorganisms 
through retention of particulates greater than the pore size of the filter. If the pore 
size is too small, the filters may become clogged resulting in increased filtration times. 
Conversely an inappropriately large filter pore size may yield greater product loss due 
to an increased "hold-up" volume.30 "Hold up" volume is defined as the amount of 
residual water in a filter after a flush of pressurized air. 50 Other important factors 
influencing the removal of microorganisms are: electrical charge interactions, the pH 
of the solution, the temperature and the pressure or vacuum applied to the filtration 
system.36 A series of multiple filtration steps must occur to remove debris; particles, 
bacteria and other molecules prior to the final sterilizing fill operation. 37 Final 
sterilization filters are generally less than or equal to a 0.22 µm pore size and must 
ensure sterility but minimize protein adsorption.49 The sterilized product is then 
aseptically filled into vials and partially stoppered, before being loaded into the 
lyophilizer. Excessive fill speeds may result in product foaming and protein 
denaturation, while long filling periods may cause protein interactions with tubing 
and equipment.30 
Lyophilization 
Lyophilization is the process of "freeze-drying" thermally sensitive products 
in order to preserve them. During World War II, lyophilization was heavily adopted 
to preserve biological materials, namely human plasma.52 Since that time, 
lyophilization technology has improved but the basic method has remained the same. 
As shown in Figure 7, the product is first frozen in order to solidify the liquid, then a 
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majority of the ice is removed through sublimation during primary drying, and then 
the small amount of remaining water is removed by desorption during secondary 
. 51 drymg . 
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Figure 7. Schematic diagram showing how the product temperature (---) differs from 
the shelf temperature (-) in the stages of a standard lyophilization cycle without an 
annealing step. 'A' denotes the water supercooling in the solution.57 
Freezing 
The freezing step is required to bring the material to a solid state before drying 
by sublimation and evaporation. Freezing is responsible for the internal structure of 
the final product, its specific area, and orientation.52 When freezing is complete, the 
system consists of a solid (in the ice form), with concentrated amorphous solutes. 
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Only rarely do the solutes become crystalline, but more commonly, the solute is 
amorphous below the glass transition state (T' g). Crystalline molecules are arranged 
in a highly ordered repeating fashion, while amorphous molecules are disordered and 
. 53 
megular. 
Product vials containing the filled formulation are placed on the lyophilizer's 
shelves, which may be pre cooled, and use circulating chilled fluid to remove heat. 
Freezing cycles then ramp the temperature of the shelves well below the customary 
phase transition freezing temperatures (Tf), known as supercooling. 53 The ice 
nucleation event occurs when the first ice crystal(s) form and then grow in size away 
from the cold surface. 54 Ice nucleation initiation may be accelerated by supercooling, 
but is also dependent on the condition of the solution and its container. 55 The release 
of heat from crystal formation temporarily raises the product temperature, and then 
progressively decreases relative to the equilibrium melting point of the concentration 
solution.56 Ice crystals grow throughout the system, leaving "interstitial fluid" 
(remaining liquid solution), yielding more concentrated proteins and excipients in the 
solute (between the ice crystals).57 Solidification is completed slowly as the heat of 
crystallization is transferred from the solidification interface through the solidified 
layer and the vial bottom to the shelf. 55 Solidification of the maximum concentration 
of the solutes occurs below a derived temperature, known as the eutectic temperature 
(Te).54 If the solute does not form a true eutectic, a "glass transition" (T'g) is reached. 
After reaching the T' g, ice begins crystallizing out as the solute solubility is exceeded 
and solute precipitation occurs as either an amorphous mass, crystals, or a 
combination ofboth. 57 Viscosity and rigidity increase as the solute concentration 
17 
increases and product temperature decreases, until water is no longer removed from 
the concentrated solution by freezing and the material solidifies into the amorphous 
form .54 Most drug products do not have fully crystallized solutes, but form an 
amorphous glass with no eutectic temperature. Instead there is a collapse temperature 
(Tc), which defines the maximum product temperature for the freeze-drying cycle, 
and is customarily a few degrees above (T' g). 56 
The ramp rates for product cooling vary and must be understood because the 
slower the crystal growth, the larger the crystal. 55 The crystal size affects sublimation 
rates and the size of the voids created in the dried material after ice has sublimed 
away during drying. Larger ice crystals leave larger voids for sublimed water vapor 
to escape through.56 These voids will improve the mass transport of water out of the 
drying cake, but larger product crystals can act as a barrier which slows this process. 54 
Annealing 
For pharmaceutical products, the crystallization of the water into ice is not 
often a problem; but the crystallization of the solutes can be difficult. Annealing is a 
process step that holds the product at a specified temperature in order to enable solute 
crystallization growth. Generally, the product is held at 10°-20°C above T'g for 
several hours to allow crystallization.53 When the product is held above T'g, the 
smaller ice crystals will melt first and cause a surface-tension-driven process that 
consolidates high-surface area particles (small crystals) into crystals with lower-
surface area particles (large crystals).58 
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The thermal cycle or "annealing" step is not mandatory for the successful 
lyophilization of all products, but has been shown vital for many products. The 
benefits of annealing are seen throughout the remainder of the cycle. These benefits 
include increased drying rates and reduced vial-to-vial heterogeneity in primary 
drying, and subsequently result in a shortened lyophilization cycle overall.58 Final 
products exhibit reduced protein unfolding in the dried solids, less aggregation and 
fewer bubbles after reconstitution, and improved pharmaceutical elegance.59 
Primary Drying 
The ice formed during the freezing step is removed by sublimation at sub-
ambient temperatures (-30°- +10°C) under vacuum (40-400 Torr). Heat is transferred 
from the shelf to the frozen solution through the tray and vial, then conducted to the 
sublimation front. 57 The partial pressure of water vapor must be reduced below the 
triple point pressure (PTP) of water to allow sublimation to occur.56 During 
sublimation, the product temperature remains low due to evaporative cooling and 
vacuum conditions, therefore heat must be provided to the product to ensure the 
process continues at an acceptable rate.54 To prevent the melting of ice back into the 
product, the temperature and pressure must be kept below the triple point. The T' g is 
the maximum allowable product temperature during the primary drying step.60 
Exceeding T' g during primary drying may result in the collapse of the highly porous 
amorphous matrix. The point at which the collapse occurs is referred to as the 
collapse temperature and is generally a few degrees higher than T'g and results in 
rejection of the final product.58 A collapsed product has lost its pharmaceutical 
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elegance, and may lead to increased residual moisture content, uneven distribution of 
moisture, longer reconstitution times, and possible changes in protein 
conformations.30 After the ice sublimes, the water vapor formed passes through the 
dried portion of the product to the surface. 57 The formation of the crystal structure of 
the product is the rate limiting factor for sublimation. Slowly frozen products with 
large ice crystals experience less resistance to the sublimed water vapor, due to large 
openings and interconnected channels. Quickly frozen products, with smaller ice 
crystals, will encounter greater resistance to water vapor because vapor flow must 
pass directly through dried material in order to escape.54 Escaped water vapor is 
transferred from the surface of the product through the chamber and then condensed 
on the condenser. 57 The condenser operates between -50°and -70°C, with a vapor 
pressure gradient resulting in a "vacuum pump," driving the process from the product 
(high pressure) to the condenser plates (low pressure).54 When all crystalline solvents 
have disappeared, the temperature is raised for the extraction of the remaining 
unfrozen liquids, known as secondary drying. 52 
Secondary Drying 
Secondary drying removes absorbed water from the product that had not 
previously separated out as ice during freezing and subsequently had not undergone 
sublimation.57 Remaining bound moisture may be water of crystallization, randomly 
dispersed water in a glassy material, intracellular water, or absorbed water.56 The rate 
of drying is fast initially but slows as the product dries; drying is increased by higher 
shelf temperatures (25°-50°C), but is product specific. 53 The product temperature 
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during secondary drying must be considered for heat labile products which may 
experience significant degradation at high temperatures. 57 The glass transition curve 
(Tg) gives the maximum temperature at which the "dry" product remains in the 
glassy state. If the temperature exceeds Tg for a sustained period of time or too great 
a temperature margin, there will be significant rates of deterioration. 61 The rate of 
drying is also dependent on product consistency with dilute solutions drying quicker 
than concentrated solutions because of higher surface areas. The rate limiting step is 
the diffusion in solid and/or evaporation at the solid/vapor boundary, and is not 
chamber pressure dependent. 53 Zero percent moisture in the product is unattainable, 
therefore the goal is <l % for optimal drug stability.57 
Upon sufficiently drying the product, the vials are stoppered in place by 
compression of the chamber shelves onto the top of the stoppers. The final 
stoppering phase is essential to ensure that the newly formed solid products are not 
contaminated later on the manufacturing line.6 The vials are then capped and crimped 
to further protect the product during shipping and consumer handling. The vials are 
then inspected, manually or automated, under appropriate criteria with an established 
predefined rejection rate for failed products.3° Finally, vials are labeled and packaged 
for shipment. 
Specific Problems with FVIII 
(BDDrFVIII)- Background 
The structure of human FVIII protein can be categorized into three major 
regions: the N-terminal 90-kd (Kilo Dalton) heavy chain, a C-terminal 80-kd light 
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chain, and a large central region designated as the Beta domain, seen in Figure 8.62 
The B-domain has been deleted to create the smallest active form of factor Vill, an 80 
and 90 kDa heterodimer linked by a metal ion. 16 BDDrFVill SQ, where SQ refers to 
amino acid linkage (serine 743-glutarnine 1738), is a genetically engineered 
recombinant product. 63 The secondary structure of this protein consists of 41 % ~-
sheets, 14% a-helix, 26% random structure, and 19% turns as defined by circular 
dichroism (CD)40 Due to the complexity of this molecule, a complete high resolution 
three dimensional understanding has not yet been achieved, and only specific 
. b "d "fi d 64 domams have een 1 entI 1e . This product does not require the addition of 
human serum albumin as a stabilizer in the final formulation. 62 
Heavy chain 
90 kO<l 
Connecting region 
110 ~D~ 
SQ-link~ SFSQNPPVLKRHQR 
741- - -745 
1637· - - - - - - - - - - - - - 1 (,48 
Light chain 
80 kO.i 
t In vivo process in& 
Figure 8 The structure of the B-domain deleted factor Vill16 
The molecule is sensitive to physical and chemical degradation because the 
molecule contains: glycosolated protein chains, seven disulfide bridges, five 
sulfhydryl groups, and a metal ion bridge.40 Physical modifications affecting the 
molecule include: elevated environmental temperatures inducing conformational 
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changes, as well as higher ionic strength yielding precipitation, which results in 
irreversible aggregation. Potential chemical reactions including: oxidation, 
deamidation, dimerization, disulfide exchange, that yield chain separation and 
ultimately irreversible aggregation.63 Extensive research on the chemical and 
physical degradation ofBDDrFVill SQ has been explored previously and is 
summarized in Figure 9. 
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Figure 9. Schematic diagram of physical and chemical transformations affecting r-
VIII SQ.63 
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§_!atement of Problem 
Recombinant FVill was chosen as a model protein for this experiment due to 
observed sensitivities during manufacturing. The primary aim of this study is to 
explore the root causes of protein loss and approaches to minimize the loss of 
BDDrFVill SQ during the manufacturing of the drug product. Three areas of interest 
were defined in order to create a comprehensive and methodical approach. 
1. Analysis of the effects of the lyophilization process through a "step-wise" 
approach, by dividing the process into three separate steps; freezing/annealing, 
primary drying, and secondary drying. Each step was individually tested to 
determine product concentration in an effort to evaluate "critical" process 
steps and potential sites of protein loss. 
2. Comparison of the protein recovery between untreated vials, siliconized vials, 
and silicone dioxide treated vials. Using a different vial represented a 
potential change that could be made to the existing product without altering 
other aspects of the process. 
3. A fortified fonnulation, referred to as the 2X formulation because it contained 
twice the concentration of excipients and proteins, was assessed. The 2X 
formulation was studied under processing conditions to determine protein 
recovery. The protein lost between the traditional formula and the fortified 
formula was compared to further evaluate the current formula. 
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Materials 
Bulk r-VID SQ (5000 IU/mL) was produced by Wyeth BioPharrna (US) and frozen at 
-80c:iC, and manufactured in a pilot scale laboratory described below in the methods 
section. Standard product samples were formulated to 275 IU/mL with a 2mL fill 
volume. A 550 IU/mL product for the 2X formula study contained double the 
formulation buffer and only a lmL fill volume. 
The excipients: L-Histidine, sodium chloride, sucrose, calcium chloride dihydrate, 
and polysorbate 80 (veg) were of pharmaceutical quality. Sodium chloride was used 
as a bulking agent and to enhance the solubility of the protein. Sucrose (beet) acted 
as a product stabilizer ( cryoprotectant) by substituting for water in the amorphous 
phase of the lyophilized product. L-Histidine buffered the formula to approximately 
pH 7.0, while calcium chloride dihydrate preserved the metal ion bridge linkage in 
the protein. Polysorbate 80 was used as a surfactant to minimize surface denaturation 
and adsorption. 17 
Durapore Polyvinylidene Fluoride (PVDF) 0.22 µm filters (Millipore, Sweden) and 
Millipore Stericup® were the sterile filters and collection containers used. Three 
different type 1 glass product vials were evaluated based on their surfaces to 
determine their effects on protein yield after reconstitution. Schott® (Germany) Type 
I tubing vials size 10 ml and 6 ml were used. Untreated glass vials were used as the 
standard by which all other vials were compared. Siliconized vials, contain a non-
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ionic aqueous emulsion of a medium-viscosity Baysilone® Fluid M (Bayer, Germany) 
surface coating. Schott Type I+® coated vials contain a quartz like inner surface of 
pure 100% silicon dioxide (Si02) coating of 0.1-0.2 µm thickness, while the glass 
matrix is comprised of 75% Si02. Vials were stoppered with a bromylbutyl rubber 
stopper FM 157 (Helvoet, Sweden) and crimp sealed with an aluminum flip-off seal. 
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Methods 
The bulk drug substance was thawed at 22°C (+/-2°C) by complete submersion in a 
water bath. The bulk drug volume needed to formulate 275 IU/ml and the amount of 
(beet) sucrose needed for a concentration of 6 mg/ml based on bulk substance volume 
was calculated. Sucrose was dissolved in a portion of the buffer while stirred. Bulk 
drug volume was diluted with buffer and sucrose in buffer to 275 IU/mL, in a non-
sterile bottle, and then agitated/inverted. Formulated drug solution was filtered 
through a 500 ml Millipore® polyvinyldiene flouride 0.22 µm unit under aseptic 
conditions in a biological safety cabinet 
Vials were labeled and filled with formulated drug using a repeater pipette to 2 mL. 
Ten 1 mL aliquots were taken in polypropylene containers for pre-lyophilized 
samples and frozen at -80°C. Thermocouples were added to each type of vial in order 
to monitor the thermodynamic environment of the product. Vials were stoppered 
according to the experimental variation planned. Freezing studies stopped prior to the 
drying stages were fully stoppered and crimped. Experiments evaluating drying steps 
only partially stoppered and subsequently crimped at the end of the cycle. 
Lyophilization was performed on pilot freeze-driers (Edwards, Germany and Lyostar, 
Netherlands), with approximately 0.43m2 usable shelf area and 25 kg ice condenser 
capacity. The vials were placed on the lyophilizer shelves at ambient temperature and 
the lyophilization cycle was run as seen in Table 1 and Figure 10. 
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Table 1. Lyophilization cycle with annealing 
~emp (°C)~ime (min)JPressure (mTorr)Elapsed time (hrs) 
~adin_g_ 25 760000 0 
!Pre-cool ramp o 30 76oooc o.5 
Wre-cool 
!Freeze ramp 
0 30 760000 1 
-55 270 760000 5.5 
!freeze 
jAnneal ramp 
-55 120 760000 7.5 
-35 60 760000 8.5 
~eal -35 24( 760000 12.5 
!Re-freeze ramp 
!Re-freeze 
!Primary drying ramp 
-40 30 760000 13 
-40 12Q 50 15 
-25 60 5C 16 
!Primary drying -25 1800 50 46 
Secondary drying ramp 40 480 35 54 
Secondary drying 40 180 35 57 
Figure 10- Full lyophilization cycle with annealing 
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The lyophilization cycle was stopped and tested for concentration at each stage of the 
cycle. An extended hold at the approximate product temperature during primary 
drying (after carrying out the cycle through annealing) to isolate temperature as a 
variable, and exclude water removal as a variable. The removal of the annealing step 
from the lyophilization cycle was evaluated and the modified cycle can be seen in 
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Table 2. A comparison between the cycle with and without annealing during 
lyophilzation start-up can be seen in Figure 11. 
Table. 2 Lyophilization cycle without annealing 
em (°C) ime (min) Pressure (mTo lapsed time (hrs) 
0 
76000 0.5 
76000 1 
76000 5.5 
7.5 
9.5 
39.5 
47.5 
50.5 
Figure 11. Lyophilization Startup- Comparison between annealing and not annealing. 
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cycle is identical to Figure 10. 
* 
Upon completion of the lyophilization cycle, the vials were fully stoppered under full 
vacuum. The vials were removed from the lyophilizer and aluminum caps were 
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crirnped to seal the product. The final product was reconstituted with 4 ml of normal 
saline (0.9%) injection (Abbott, Illinois). For the lyophilization study, samples were 
reconstituted or diluted dependent on their final form. A 4 ml of normal saline 
injection was added to all products that had a cake structure; including samples 
stopped after primary drying and secondary drying. While samples removed prior to 
drying, (frozen and annealed samples) were diluted with 2 ml of 1.8% sodium 
chloride solution to ensure equivalent ionic strength of commercial products. Only 
the extended freeze and hold study received 2 ml of 0.9% sodium chloride solution, 
(half of the standard salt concentration addition), which resulted in further ionic 
strength studies to evaluate the effects of varying ionic strengths and volumes for 
reconstitution. Four milliliters of reconstituted solution contained 137.5 IU/ml of 
FVID, 18mg/ml sodium chloride, 3.0 mg/ml sucrose, 1.5 mg/ml L-histidine, 0.25 
mg/ml calcium chloride dihydrate, and 0.1 mg/ml polysorbate 80. 
The concentration of FVIII was determined after reconstitution or dilution, using 
HPLC. A chromogenic bioassay was used to detennine potency. Due to the inherent 
variability in bioassays and data showing similar trends as the concentration assay, 
potency was not determined for the majority of the samples. 
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Analytical Methods 
Chromogenic bioassay of Factor VIII activity 
The Cobas Fara II (Roche) employs a two-step kinetic chromogenic substrate method 
(Coatest® Factor VIII, Chromogenix AB, Sweden)65 , used to measure FVIII activity. 
Activated factor X (Xa) is generated via the intrinsic pathway where factor VIII:C 
acts as a co-factor, seen in fig. 12.63 
Figure 12. COBAS-FARA (2 Step Kinetic Chromogenic Bioassay)- Step 1 
x IX a + Ca+++ phosp/Jolipid Xa 
VIII: C 
Factor Xa is then determined by synthetic chromogenic substrate, S-2222, in the 
presence of a thrombin inhibitor, I-2581, to prevent hydrolysis of the substrate by 
thrombin, as seen in figure 13. 63 
Figure 13. COBAS-FARA (2 Step Kinetic Chromogenic Bioassay)- Step 2 
Substrate Xa Peptide pNA 
The reaction is stopped with acid, and the release of pNA (para-nitroaniline), which is 
proportional to the VIII:C activity, is measured photometrically at 405 nm against a 
reagent blank. 66 The activity of factor VIII:C is expressed in international units (IU) 
as defined by the current International Concentrate Standard (IS) established by the 
World Health Organization (WHO). The assay variability was found to be 10-12% 
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and was subsequently used only initially to find a correlating trend between 
concentration and potency. 
Factor VIII concentration 
Factor Vill concentration (µg/ml) was determined using an anion exchange high 
performance liquid chromatography (HPLC) with ultraviolet (UV) and florescence 
detectors. Components from a sample were separated by differences in their charge, 
and an exchange of their charged analytes with the counter ions electrostatically 
bound to the oppositely charged functional groups on the column's stationary phase. 
The HPLC system (Waters®, US) consisted of: 2695 HPLC, 600S Controller 6DC, 
474 Scanning Fluorescence Detector, 2487 Dual Absorbance Detector, 717 Plus 
Autosampler. A Mono Q® HR5/5 (Pharmacia Biotech, US) anion exchange column 
was employed. Two mobile phases were used to create the anion gradient; mobile 
phase A (20mM Tris, pH 7.5) and mobile phase B (20mM Tris, lM NaCl, pH7.5). 
The system was first flushed with purified water and then equilibrated using 
the mobile phases. The anion gradient is formed by running a weak eluent with low 
mobility (mobile phase A) and then running a strong eluent with high mobility 
(mobile phase B).67 A standard curve was prepared using five samples from a 
diluted stock solution ofFVill (Wyeth BioPharma, US) from a linear regression 
model. The lyophilized samples were reconstituted with 4.0 ml of 9 mg/ml NaCl. 
The liquid is then swirled gently, and the solution should not touch the stopper during 
mixing. 350 µL of the mixed sample is transferred to the Millipore© sample vials. 
Samples were then loaded into the HPLC autosampler (4°C) and drawn in triplicate 
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injections. Each sample injection ran for 17 minutes, all vials had their first sample 
drawn before beginning, the second and third injections. This sequenced method for 
multiple injections from the same vial ensured that vials tested later in long runs did 
not experience vastly different environmental exposure times to those vials tested first. 
A minimum of 10 vials per sample with triplicate injections yielded a total of 30 data 
points (n=30) for greater power in the studies. The 550 ill/vial products that were 
analyzed for concentration demonstrated approximately 4% relative standard 
deviation. Figure 14 is an example of an FVill chromatogram. 
Sample Information 
Sar'l'lel'erre Tubing 631 5arTple Type Lhknow n 
Vial 73 Date Acquired 7/21/0412:3Q:03AM 
t-jection Acq Method Set rronoQ_conc_uvf[.Alliance 
t-jectionVokm! 100.00ul Pl"ocessilg Method Lyostar2 
Chamel SA1'11 Data Pl"ocessed 7/22104 3:29:33 Fiii 
A..nTrm 17.0 l'Mutes 
Auto--ScaJed Chromatogram 
120. 
100. 
80. 
> 
E 
80. 
... 
20. 
0. 
2-00 4.00 6.00 8.00 10.00 12.00 14.00 18.00 
-..nufff 
- • Sarrplef\Srre Tubing E3 1 t-jection 1 
Peak 11 .. u1t1 
Name RT Heii;1t Alee % Area Total Area Amount Units 
1 ReFacto <4 .851 118344 2556421 100.00 2555421 8.90 u(jml 
Figure 14. Sample of Factor Vill HPLC Chromatogram 
Statistical Methods 
JMp 5.1 (SAS Inc., US) was used for all statistical analysis of the data. The data 
underwent a summary of fit, a student t test, and a one-way analysis of variance 
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(ANOV A). The ANOV A data is presented in this paper in the form of the one-way 
ANOVA diamonds and x-Axis proportional model, a sample is seen in Figure 15.68 
Figure 15. An explanation of means one-way ANO VA diamonds and x-Axis 
proportional model 
group mean 
F M 
/:· 
x-axis proportional 
Total Response 
Sample Mean 
ANOV A uses a test of the null hypothesis by comparing two sets of 
differences; the first set compares external (between groups) differences, and the 
other is an internal (within-group) differences. This allows the measurement of 
experimental treatment and experimental error (external), compared with 
experimental error alone (within-group). The test calculates the F-ratio; the model 
mean square divided by the error mean square and determines whether the variability 
between the groups is large enough in comparison to the variability of data within 
each group to justify the difference in groups.69 
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R,.esults and Discussion 
Lyophilization Cycle Experiments 
Lyophilization Cycle Examination-A step-wise approach 
Based on the assumption that protein concentration loss occurs during lyophilization, 
partial cycles were run to identify the stage(s) during which it occurred. These partial 
cycles were stopped after annealing and primary drying, and those recoveries were 
compared to that of a full cycle. 
Figure 16 shows each step of the cycle and the mean quantity of protein recovered as 
a percentage of the pre-lyophilized samples frozen at -80°C. The loss of protein 
during lyophilization is negligible within the accuracy of the assay compared to the 
loss upon freezing. This data demonstrates that freezing may act as the greatest 
contributor to protein loss, while other stages have less impact. Full data and 
statistical analysis are found in appendix III. 
35 
Figure 16- Protein concentration recovery as a percentage for each step of the 
Jyophilization cycle. 
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The degradation of protein as a function of the freezing rate has been investigated in 
model proteins previously. Lactate dehydrogenase (LDH) was found to lose a greater 
amount of activity (U/mL) after being frozen slowly in a freeze-drier, than when 
rapidly frozen with liquid nitrogen. 4 The rate of freezing determines the size of the 
ice crystals formed, with slow freezing yielding larger ice crystals.55 Due to larger ice 
crystal formation in the product there may be greater shear force exerted on the 
protein molecules by the ice crystals, causing degradation. 70 Additionally, the 
increased concentration of protein and excipients found in the unfrozen portion of the 
product during freezing increases the ionice strength, a pH shift, and protein 
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dehydration. These factors increase the probability of "biomolecular collisions'',53 
which can yield instability and aggregation. 
Finally, the weakening of hydrophilic interactions between protein and water 
molecules can result in more "free water" removed during ice crystal growth, and 
result in greater protein unfolding and/or denaturation. 71 Conversely, the rapid 
freezing of a product may result in less protein lost because the solution yields a large 
number of small ice crystals that causes less solutes to concentrate in the remaining 
unfrozen areas.72 Rapid freezing also may decrease the amount of water removed 
. 4 from proteins. 
There is conflicting literature on the topic of freezing rate. Some hypothesize that the 
larger ice surface areas stress the proteins greatly and believe that surface 
denaturation may play a role during the freezing of proteins. 73 The varied views may 
be the result of protein specific activity during the freezing process, and cannot be 
generalized by the rate of freezing alone. 
Lyophilizationfreeze and hold study 
An extended "hold" at the approximate product temperature during primary drying 
(after carrying out the cycle through annealing) was performed and isolated 
temperature as a variable. By holding the samples above their T'g, the proteins were 
exposed to a longer period of time, allowing destabilizing reactions to occur and yield 
an unstable product. This study excluded the rate of water removal as a variable 
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because primary drying was extended long enough to ensure all sublimated water was 
eliminated. As a control, a lmL sample of pre-lyophilized product in polypropylene 
(PPE) tubes was frozen rapidly in a -80°C freezer. These samples were tested 
without dilution, and pipetted numerous times to prevent stratification, and exposed 
to a smaller amount of surface area as compared to the standard product. 
Figure 17 below, shows that there is no significant loss when the product is frozen, 
annealed, and held in a lyophilizer at simulated primary drying conditions without a 
vacuum, than when samples are frozen in a polypropylene (PPE) tube in a -80C 
freezer. 
Figure 17. Concentration (µg/mL) results for the Freeze/Hold study without dilution. 
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In an effort to more closely mimic the actual product, additional samples were diluted 
with 0.9% NaCl, then agitated and inverted, as they would be during reconstitution. 
Table 3 shows a significant loss is experienced when the product is diluted. 
Table 3. Freeze/Hold Study- Diluted with 0.9% NaCl 
Stage of Cycle 
Freeze/hold with no dilution 
Freeze/hold with 0.9% NaCl dilution 
Protein Recovery(%) (calculated 
compared to pre-lyophilzation sample) 
95.9% (5.5% RSD) 
76.0% (8.7% RSD) 
During freezing loss of product is not seen until after dilution, suggesting that a 
potential surface denaturation of protein could occur at the ice-water interface.73 This 
denaturation coupled with the change in protein and excipient concentration, and/or 
the additional handling and agitation may be responsible for magnifying the loss. The 
process of dilution and agitation/inversion exposed the liquid product to a greater 
surface area of the glass vial, where there may be a potential for adsorption of protein 
to the glass surface. The two predominant methods of protein adsorption to 
pharmaceutical containers are charge-charge (electrostatic) interactions and 
hydrophobic interactions with dehydration of the protein and the surface.34 The 
potential protein-glass interaction was evaluated and can be seen later in this paper. 
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The thawed product contained a volume of 2mL and received 2mL of 0.9% NaCl to 
bring the product to the proper volume. This adjustment did not meet the ionic 
requirements of the commercial product which would have required the addition of 
2mL of 1.8% NaCl. Further studies were performed to evaluate the ionic strength of 
the reconstituted product and the effect on recovery. Three diluents: water, 0.9% 
NaCl, and 1.8% NaCl were added in different volumes: lmL, 2mL, and 4rnL to 
lyophilized samples. Reconstitution of the lyophilized cake with 4 ml of 0.9% NaCl 
yielded 50.10 (µg/ml), 4 ml of 1.8% NaCl yielded 50.63 (µg/ml), and 4 ml of water 
yielded 48.6l(µg/ml). Reconstitution with only water yields a lower amount of 
protein recovery and the reconstitution volume does not significantly affect the 
amount of protein recovered after reconstitution. This loss may be attributed to a lack 
of ionic protection due to a lack of proper NaCl concentrations. Complete 
experimental data is found in appendix ill. 
Evaluation of the annealing step 
Many protein drugs are manufactured through a lyophilization cycle that does not 
require an annealing step. To investigate the effect of annealing on recovery, a full 
lyophilization cycle was run with the annealing step omitted, the results are seen in 
Table 4. 
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Table 4. Protein Recovery as a percentage between lyophilization cycles that anneal 
and do not. 
'Stage of Cycle Protein Recovery(%) (calculated 
com_£ared to _1>_re-!_~0_1>_hilzation sam_£le) 
Complete Cycle 80.8% (8.2% RSD) 
Cycle without annealing 70.4% (20.2% RSD) 
Figure 18: Concentration (µg/mL) oflyophilized products with or without an 
annealing step after reconstitution 
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The lyophilization cycle with the annealing step showed greater recovery of protein, 
as seen in figure 18. Annealing has been shown to relieve residual stress, which is 
correlated with protein unfolding in the dried solids and less aggregation after 
reconstitution.74 Annealing decreases the variation in initial ice crystal size 
distributions caused by unpredictable nucleation temperatures and allows the uniform 
drying rates of the product. 58 This heterogeneity of drying rates may have caused the 
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unusually large relative standard deviation (20.2%) for the unannealed cycle. 
Research has also shown that removing the annealing step can have a detrimental 
effect on the final lyophilized cake structure.75 Poor pharmaceutical elegance, weak 
cake structure, the formation of bubbles upon reconstitution, and increased drying 
rate heterogeneity are examples of negative effects that may occur in unannealed 
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Glass vial experiments 
This study compared three different types of Schott® Type I glass tubing vials; 
untreated, silicon dioxide coated (Type 1 Plus®), and siliconized. Research had 
shown FVIII adsorption to the vial surface to be a mode of protein loss63 and was 
evaluated by comparing the differently treated vials. 
Because of delayed shipments of siliconized vials, the two types of treated vials 
available were not the same size. Each of the treated vial types were compared to 
untreated vials of the same size. Unfortunately comparing the two types .of coated 
vials to each other was not possible from this data because of the difference in surface 
area. 
Siliconized vs. Untreated Glass Vials 
Comparison of siliconized vials and untreated vials, when lyophilized but not 
annealed in a simulated "worst case scenario." 
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Figures 19 and 20 show that a siliconized vial yields a significantly higher recovery 
of protein when tested for concentration (µg/mL) and potency (IU/mL). 
Figure 19: Siliconized vs. untreated vials- Concentration (µg/mL) by Mono Q HPLC 
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Figure 20: Siliconized vs. Untreated Vials- Potency (U/mL) by COBAS-FARA 
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Type J Plus® vs. Untreated Glass Vials 
This experiment compared silicone dioxide coated vials and untreated vials, when 
Jyophilized under the current commercial cycle. Figure 21 below shows that the 
Schott Type 1 + coated vial yields a significantly greater recovery of protein than an 
untreated vial. 
Figure 21. Mean Concentration (µg/mL) of untreated vials vs. silicon dioxide (1+) 
vials 
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Adsorption of proteins to surfaces due to their amphipathic nature has been widely 
recognized due to multiple binding sites on the protein and mixed-site nature of 
substrates.76 This is especially apparent when products contain low overall 
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concentrations of active products, and a small concentration of protein adsorbed to 
the vial wall may result in a significant loss in product concentration.39 Previous 
studies have shown that structurally altered forms of the protein may appear on 
surfaces because of: 1) Pre-existing distribution of conformations in the solution 
phase 2) Rapid conformational changes accompanying adsorption 3) Slow 
conformational changes after adsorption.76 Previous studies addressing adsorption of 
protein to glass vials, found that in general proteins appear to saturate at 
approximately 5µg/mL of protein, with a maximum of 10-15% protein adsorption and 
the degree of binding based on individual proteins.39 This may represent a significant 
loss for the product, which contains 10.5-11.5 (µg/mL). Proteins have been shown to 
experience different mechanisms of bonding to untreated glass vials and silicone 
treated vials. Proteins bind to untreated glass through ionic amine bonding, and an 
aggregative force between silica and proteins. 38 Proteins exposed to untreated glass 
surfaces two rates ofreactions occur: 1) a rapid rate of adsorption based on the 
number of amines in the protein, 2) a slower rate of adsorption due to the protein's 
molecular weight, which determines the rate and extent of protein diffusion into the 
porous structure of the glass. 77 Proteins bind to silicone treated glass through 
hydrophobic bonding between aliphatic (hydrocarbons without benzene rings/8 
residues on proteins and silicone residues on coated glass.38 
Both vial coatings (silicone and silicon dioxide) improve recovery and decrease 
sample variability compared to untreated vials. It can be speculated that vials that 
have been treated have less surface charge and attract less protein to adsorb to the vial 
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walls. However, substituting a treated vial would yield an approximately 5% greater 
recovery of protein than an untreated vial. While there is a significant cost 
associated with the drug, expenses associated with the new vials and their 
implementation must be considered for a more accurate cost to benefit rationale. 
Formulation Study 
J X versus 2X formulation 
This study compared the lX and 2X formulations ofBDDrFVill SQ to determine 
whether the concentrated formula yields greater protein recovery. Schott Type I 
Plus® coated vials were tested to determine the effects on recovery for the 
concentrated formulation . 
Figure 22- Recovery of protein (µg/mL) when comparing lX and 2X formulations in 
both coated and untreated vials. 
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Table 5. Comparison of the recovery of protein as a percentage of the initial frozen 
polypropylene concentration. 
Stage of Cycle jType I Untreated rrype I Plus® Coated 
80.0% (8.2% RSD) 86% (2.2% RSD) 
lX formulation w/ 4mL 0.9% NaCl Recon 
12X formulation w/ 4mL 0.9% NaCl Recon 89.2% (5.8%) 87.8% (2.3%) 
Figure 22 and Table 5 show that there is a significant improvement in the untreated 
vial when the 2X formulation is used. The recovery is approximately the same for 
both formulation strengths in the Type I Plus® coated vials, which suggests that an 
increase in formulation strength and the vial coating may alleviate similar problems. 
This improvement may be attributed to the excipient concentration, which has 
doubled and provided greater cryoprotection, lyoprotection, and/or overall stabilizing 
effects. Additionally, the decrease in water per unit volume for the product fill may 
also result in less potential ice surface area to damage the protein, as discussed in the 
lyophilization experiment section. 
The increased concentration of excipients may protect the protein from denaturation 
during freezing. This protection during freezing is explained by the Theory of 
Preferential Exclusion states that excipients are preferentially excluded from protein. 
This exclusion results in a decreased ratio of the native conformation's surface area to 
the solution, which is thermodynamically preferred over the denatured state.79 This 
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mechanism describes how solutes such as salts and sugars can stabilize proteins 
during freezing, thawing, and in liquid solution. 
Increased ionic strength through the addition of sodium chloride to the formulation 
may decrease aggregation ofBDDrFVIII SQ. Fatorous, et al. compared 5.8 mg/ml 
and 58mg/ml of sodium chloride with regard to total aggregate formation, the higher 
salt concentration formula was found to be advantageous. The stabilization of the 
drug was attributed to interactions affecting specific ion binding, and the exclusion of 
salt from contact with the protein to cause preferential hydration.80 
The effects of increased concentrations of surfactants (Polysorbate 80) in a 
BDDrFVIII SQ formulation were previously studied. 16 The Osterberg, et al study 
was used to determine the optimal amount of polysorbate 80 for the albumin free 
formulation of the product. While 0.1 mg/ml of polysorbate 80 was chosen, data 
presented in the study indicated that at higher concentrations (0.25 mg/ml and 0.4 
mg/ml) yielded factor VIII activity that was equivalent (in one circumstance) and 
usually greater. Surfactants have been shown to reduce protein adsorption to surfaces 
and aggregation-induced denaturation, while protecting against thermal degradation 
and freeze-thaw induced degradation. 81 
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§_tudy Limitations 
This study was designed in a methodical and scientific manner, but caution must be 
taken not to generalize the results of this study. This study was performed in a 
research laboratory and not in a commercial or clinical scale plant. All of the 
processing was performed manually and at a significantly smaller scale than the 
product would normally undergo. Commercial manufacturing enjoys a greater degree 
of automation and an advantageous volume to processing surface area than was seen 
in this study. Additionally the laboratory equipment operates and affects the product 
differently than would be experienced in the COII11Uercial scale. While effort was 
made to minimize equipment, operator, or scale variability, it is a factor that must be 
considered when interpreting these results. 
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Conclusions and Future Work 
The primary aim of this study was to determine the primary causes of protein 
Joss from the BDDrFVill SQ during the manufacturing of the drug product. Due to 
the complexity of proteins and the intricacies of the drug product manufacturing 
operations, this objective was ambitious. When surveying all of the data, one can 
conclude that multiple factors contribute to the problem. 
Through observation and data analysis it has been detennined that the 
freezing step of the lyophilization cycle is the most important processing component, 
contributing to the loss of protein concentration. The current freezing cycle produces 
an ice crystal structure that damages the protein and may create an increased 
susceptibility to denaturation and aggregation upon reconstitution. Future studies 
must further analyze the process of freezing and subsequent reconstitutions. A 
comparison of different lyophilization cooling temperatures and rates, the use of pre-
cooled shelves, and the use of vacuum at different points of the cycle would further 
characterize the effects of freezing on BDDrFVill SQ. 
The use of treated vials showed a significant benefit over untreated glass vials 
in the recovery ofBDDrFVill SQ, but did not ameliorate the problem entirely. This 
indicates that the loss of protein is only partially due to protein-surface interactions 
resulting in adsorption. Further evaluations should examine siliconized, silicone 
dioxide, and untreated vials in a "head to head" study of the same vial surface areas. 
Additional studies to determine the optimal siliconization level for the siliconized 
vials for maximal protein recovery should be performed. 
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In general, samples tested from either treated vial showed less inter-sample 
variability. While this does not affect the primary goal of the study, it is of interest 
because finished products are required to be tested prior to commercial release. Less 
variability may result in the difference between the product being commercially 
released or destroyed. Studies investigating the variability of protein concentrations 
with respect to product release parameters should be investigated to fully appreciate 
the trend seen in this study. 
The use of the 2X formulation demonstrates that the problems associated with 
the product lacking protection during processing can be alleviated. Through 
fortification of the formula and the decreased amount of available ice surface area, 
there is less protein lost during lyophilization and reconstitution. Future studies 
should examine the effects of decreasing the volume of ice independently of 
formulation change, to gain insight into interactions of ice surface and the protein. 
Further investigation of new fortified formulas, such as 3x, 5x, 1 Ox, etc, should be 
studied to find the optimum protein yield. 
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Appendix I (Equipment) 
-
Equipment Name Manufacturer Model No Serial No 
(Abbr.} 
2-8°C Cold Room NIA NIA NIA 
Edwards 
Lyophilizer 
Lyophilizer L_y_ostar 
Waters 2695- HPLC Waters 2695 
system consisting of the 
following: 
Waters 600S Controller Waters 600S 
6DC D006DC 
Waters 4 7 4 Scanning Waters 474 
Fluorescence Detector L98474091M 
Waters Dual Absorbance Waters 2487 
Detector 2487 D00487304M 
Waters 717 Plus Waters 717 
Autosampler C9971P049M 
Cobas-FARA (Roche Analytical 
Centrifugal Instruments) 
Spectrophotometer 
Cobas-FARA Reagent 
Cups 
Cobas-FARA Cuvettes 
Cobas Sample Cups 
Balance Mettler 
Calibrated Pippetes (May 
04): P20, PlOO, P200 and 
PlOOO 
pH meter Orion 
56 
Appendix II: Reagents and Materials 
.--
Chemical Name Manufacturer Grade Catalog Lot Number 
No. 
r- . 
ReFactoAF Active Wyeth/GI GMP NIA #P034109m01 
Substance 
ReFactoAF Wyeth/GI 02417M01 
Concentration 
Standard 
ReFactoAF Wyeth/GI 86759-51 
Potency_ Standard 
0.9% NaCl Abbott 10 mL NDC0074-
vial 
4888-10 
Sodium Chloride Sigma USP S-1679 
Trizma Base Sigma USP #T-1503 
BSA 1% Sigma USP #A-7030 
Mobile phase A Wyeth/GI Research NIA 
for AEX-HPLC 
Mobile phase B Wyeth/GI Research NIA 
for AEX-HPLC 
AEX Column Pharmacia Research 17-0546-011 
Bio tech 
Factor IXa+X Chrom~enix Reagent NIA 
S2222 20 mg- Chromogenix Reagent NIA 
12581 
Calcium Chloride Chromogenix Reagent NIA 
Phospholipid Chromogenix Reagent NIA 
Emulsion 
MFR218 buffer Wyeth NIA NIA 
Sucrose S~a USP S7903 
MFR275 Wyeth NIA NIA 
MFR323 Wyeth NIA NIA 
t-
Millipore Millipore NIA 
'--n _______ ---- "l""\I""\ --- --
57 
,-
ourapore 0.22 µm 
filters 
I-
MillJE..ore Stericup Millipore NIA SCGPU02RE 
~illi-Q Water Wyeth NIA NIA Andover K2100 
~H 4.0 standards Fisher Research SBlOl-500 
PH 7.0 standards Fisher Research SB107-500 
58 
Appendix III 
§_ection 1: Lyophilization Cycle experiments 
1. Lyophilization cycle- "Stepwise" approach 
A. Lyophilization cycle stopped after annealing 
Oneway Analysis of Mean (Cone. Ug/mL) By ID 
35 
33 
:J" 31 E 
Ci 
::> 29 
c.i 
c 
0 27 8 
c 
ro 25 Q) 
~ 
23 
Coated Pre-Lyo Coated Pre-Lyo Tubing Tubing 
Oneway Anova 
Summary of Fit 
Pre-Lyo PPE 
ID 
Rsquare 
Adj Rsquare 
Root Mean Square Error 
Mean of Response 
Observations (or Sum Wgts) 
0.475531 
0.460547 
1.900872 
25.6989 
Analysis of Variance 
Source DF 
ID 4 
Error 140 
C. Total 144 
Means for Oneway Anova 
Level Number 
Coated 30 
Pre-Lyo Coated 25 
Pre-Lyo PPE 30 
Pre-Lyo Tubing 30 
Tubing 30 
Sum of Squares 
458.66274 
505 .86388 
964.52662 
Mean 
25 .9953 
24.50 16 
28.8600 
23.7660 
25.1720 
Std Error uses a pooled estimate of error variance 
ID N Mean 
Coated 30 25 .9953333 
Pre-Lyo Coated 30 24.5016 
Pre-Lyo PPE 30 28.86 
Pre-Lyo Tubing 30 23.766 
Tubing 30 25.172 
145 
59 
Mean Square 
114.666 
3.613 
Std Error 
0.34705 
0.38017 
0.34705 
0.34705 
0.34705 
Std Dev 
1.8414738 
0.7771244 
3.2294699 
0.47189712 
1.70311358 
F Ratio 
31.7342 
Lower 95% 
25.309 
23.750 
28.174 
23.080 
24.486 
Prob> F 
<.0001 
Upper 95% 
26.68 1 
25.253 
29.546 
24.452 
25.858 
B. Lyophilization cycle stopped after primary drying 
Onewa Anal sis of Mean Cone. U /mL B ID 
11 .5 i_ 
11 
---
t 
-_L 
-
'.J" 
E Ci 10.5-
:::> 
u 10-c 
0 
~ 
c 9.5-co 
Ql 
:::E 
9-
8.5 T 
Coated 
ID 
Oneway Anova - Summary of Fit 
Rsquare 
Adj Rsquare 
Root Mean Square Error 
Mean of Response 
Observations (or Sum Wgts) 
t Test 
Coated-Tubing 
Assuming equal variances 
-
I 
~ · . 
. 
-;-
Tubing 
0.158533 
0.142351 
0.542 159 
10.765 
54 
-
Difference 0.461852 t Ratio 
0.147557 DF 
0.757947 Prob > iti 
0.165757 Prob > t 
3.129988 
Std Err Dif 
Upper CL Dif 
Lower CL Dif 
Confidence 0.95 Prob < t 
,~I, 
-0.5 -0.3 -0 .1 .0 .1 .2 .3 .4 .5 
Analysis of Variance 
Source OF 
ID 1 
Error 52 
C. Total 53 
Means for Oneway Anova 
Sum of Squares 
2.879646 
15.284704 
18.164350 
Level Number Mean 
Coated 27 10.9959 
Tubing 27 10.5341 
Std Error 
0.10434 
0.10434 
Std Error uses a pooled estimate of error variance 
ID N Mean 
Coated 30 10.9959259 
Pre-Lyo Coated 30 26.362 
Pre-Lyo PPE 30 23.5108333 
Pre-Lyo Tubing 30 25.7566667 
Tubing 30 10.5340741 
60 
52 
0.0029 
0.0014 
0.9986 
Mean Square 
2.87965 
0.29394 
Lower 95% 
10.787 
10.325 
Std Dev 
0.25662393 
1.07727434 
2.03095376 
2.22171157 
0.7225077 
F Ratio Prob > F 
9.7968 0.0029 
Upper 95% 
11 .205 
10.743 
C. Full Lyophilization cycle 
Onewa Anal sis of Mean Cone. U /mL B ID 
35--1 
30--1 
1 1 
:::I . 
E -. 
°' 
25--1 
;:) 
cj 
c 
0 
~ 20--1 c 
ro 
Q) 
:2 
15--1 
10--1 
T I I 
Coated Pre-Lyo Coated Pre-Lyo PPE 
Oneway Anova 
Summary of Fit 
Rsquare 
Adj Rsquare 
Root Mean Square Error 
Mean of Response 
Observations (or Sum Wgts) 
0.960408 
0.959292 
1.59899 
21.06707 
147 
Analysis of Variance 
Source DF 
ID 4 
Error 142 
C. Total 146 
Means for Oneway Anova 
Level Number 
Coated 30 
Pre-Lyo Coated 28 
Pre-Lyo PPE 29 
Pre-Lyo Tubing 30 
Tubing 30 
Sum of Squares 
8806.9416 
363.0612 
9170.0028 
Mean 
12.1363 
27.4707 
28.2148 
26.7810 
11.3977 
Std Error uses a pooled estimate of error variance 
ID N Mean 
Coated 30 12.1363333 
Pre-Lyo Coated 30 27.4707143 
Pre-Lyo PPE 30 28.2148276 
Pre-Lyo Tubing 30 26.781 
Tubing 30 11.3976667 
61 
ID 
Mean Square 
2201.74 
2.56 
Std Error 
0.29193 
0.30218 
0.29692 
0.29193 
0.29193 
Std Dev 
0.2688992 
3.05278613 
1.46510999 
0.91070397 
0.93185645 
..I. 
1 
Pre-Lyo Tubing 
F Ratio 
861.1397 
Lower 95% 
11 .559 
26.873 
27.628 
26.204 
10.82 1 
I 
.I. 
T 
Tubing 
Prob > F 
<.000 1 
Upper 95% 
12.7 13 
28.068 
28.802 
27.358 
11 .975 
onewa Anal sis of Mean Cone. U /mL B ID 
13 
12.5 
~ 12 
_...J 
E 
~ 11 .5 
u 
c 
0 11 ~ 
c 
~ 10.5 
:2 
10 
9.5 
..., 
-i 
-
-
-
-
-
I 
--I 
-
..!. 
-
. 
-
~ 
. 
• 
. 
. 
• 
. 
• 
I 
. 
I 
i 
--
-
Type I Tubing- Untreated Type I+ Coated 
Oneway Anova 
Summary of Fit 
Rsquare 
Adj Rsquare 
Root Mean Square Error 
Mean of Response 
Observations (or Sum Wgts) 
t Test 
ID 
0.230783 
0.21752 1 
0.685807 
11.767 
60 
Type I Tubing- Untreated-Type l+ Coated 
Assuming equal variances 
Difference 
Std Err Dif 
Upper CL Dif 
Lower CL Dif 
Confidence 
I 
-1.0 
-0.5 .0 
Analysis of Variance 
Source DF 
ID l 
Error 58 
C. Total 59 
-0.7387 t Ratio 
0.177 1 DF 
-0.3842 Prob > ltl 
- l.0931 Prob > t 
0.95 
.5 
Prob < t 
I 
1.0 
Sum of Squares 
8.184427 
27.279233 
35.463660 
Means for Oneway Anova 
Level Number 
30 
30 
Type I Tubing- Untreated 
Type l+ Coated 
Std Error uses a pooled estimate of error variance 
-4.1715 
58 
0.0001 
0.9999 
<.0001 
Mean Square 
8.18443 
0.47033 
Mean 
11 .3977 
12.1363 
62 
Std Error 
0.12521 
0.12521 
F Ratio 
17.4014 
Lower 95% 
11.147 
11 .886 
Prob> F 
0.0001 
Upper 95% 
l l.648 
12.387 
2. Freeze and hold studies 
A. Freeze and Hold without dilution 
Onewa Anal sis of Mean Cone. U /mL B ID 
33~~~~~~~~~~~~~~~~~~~~~~-----, 
32 
31 
::::J 30 
E 29 Ci 
:::J 28 
c..i 27 c 
0 
~ 26 
c 25 cu 
Cl> 24 ::2 
23 
22 
21 
Coated Pre-Lyo Coated Pre-Iyo Tubing Tubing 
Pre-Iyo PPE Siliconized 
Oneway Anova 
Summary of Fit 
ID 
Rsquare 
Adj Rsquare 
Root Mean Square Error 
Mean of Response 
Observations (or Sum Wgts) 
0.166062 
0.142098 
1.645729 
28.07817 
Analysis of Variance 
Source DF 
ID 5 
Error 174 
C. Total 179 
Means for Oneway Anova 
Level Number 
Coated 30 
Pre-Lyo Coated 30 
Pre-Iyo PPE 30 
Pre-Iyo Tubing 30 
Siliconized 30 
Tubing 30 
Sum of Squares 
93 .84293 
471 .26577 
565.10869 
Mean 
28.3580 
29.1227 
28.5617 
26.9540 
28.0737 
27.3990 
Std Error uses a pooled estimate of error variance 
ID N Mean 
Coated 30 28.358 
Pre-Lyo Coated 30 29.123 
Pre-Iyo PPE 30 28.562 
Pre-Iyo Tubing 30 26.954 
Siliconized 30 28.074 
Tubing 30 27 .399 
180 
63 
Mean Square 
18.7686 
2.7084 
Std Error 
0.30047 
0.30047 
0.30047 
0.30047 
0.30047 
0.30047 
Std Dev 
0.750 
1.564 
2.797 
1.568 
0.848 
1.497 
F Ratio 
6.9297 
Lower 95% 
27.765 
28.530 
27.969 
26.361 
27.48 1 
26.806 
Prob > F 
<.0001 
Upper 95% 
28.951 
29.716 
29.155 
27.547 
28.667 
27.992 
A. Continued freeze and hold without dilution 
Onewa Anal sis of Mean Cone. U /mL B ID 
:::;- 30 
E 
Ci 29 
:::> 
u 28 c 
0 
~ 
c 27 
<ti 
Q) 
:? 26 
Pre-Iyo PPE 
Oneway Anova- Summary of Fit 
Rsquare 
Adj Rsquare 
Root Mean Square Error 
Mean of Response 
Observations (or Sum Wgts) 
t Test 
Pre-Iyo PPE-Tubing 
Assuming equal variances 
Difference 
Std Err Dif 
Upper CL Dif 
Lower CL Dif 
Confidence 
1.16267 t Ratio 
0.57924 DF 
2.32214 Prob> ltl 
0.00319 Prob > t 
0.95 Prob < t 
,~, 
-2.0 -1 .5 -1.0 -0.5 .0 .5 1.0 1.5 2.0 
Analysis of Variance 
ID 
0.064953 
0.048831 
2.243386 
27.98033 
60 
Source DF 
ID I 
Error 58 
C. Total 59 
Sum of Squares 
20.27691 
291.90129 
312.17819 
Means for Oneway Anova 
Tubing 
2.007229 
58 
0.0494 
0.0247 
0.9753 
Mean Square 
20.2769 
5.0328 
Level Number Mean 
Pre-Iyo PPE 30 28.5617 
Tubing 30 27 .3990 
Std Error 
0.40958 
0.40958 
Std Error uses a pooled estimate of error variance 
F Ratio 
4.0290 
Lower 95% 
27.742 
26.579 
ID N Mean(Ug/mL) 
Pre-Iyo PPE 30 28.5616667 
Tubing 30 27 .399 
Std Dev 
2.79719451 
1.49708533 
64 
Prob > F 
0.0494 
Upper 95% 
29.382 
28.219 
B. Freeze and Hold with 0.9% NaCl Dilution 
o newa Analysis of Mean Cone. U /mL B ID 
12 
11.5 
'.]' 
.§, 11 
:::> 
ti § 10.5 
S2-
[ij 10 
Q) 
~ 
9.5 
9 
Coated 
Oneway Anova- Summary of Fit 
Rsquare 
Adj Rsquare 
Root Mean Square Error 
Mean of Response 
Observations (or Sum Wgts) 
t Test 
Coated-Tubing 
Assuming equal variances 
Difference 
Std Err Dif 
Upper CL Dif 
Lower CL Dif 
Confidence 
0.87637 t Ratio 
0.19945 DF 
1.2 7 608 Prob > itl 
0.47666 Prob > t 
0.95 Prob< t 
I & I 
-1.0 
-0.5 .0 .5 1.0 
Analysis of Variance 
ID 
0.259821 
0.246363 
0.75187 
11 .26579 
57 
Source DF 
ID I 
Error 55 
C. Total 56 
Sum of Squares 
10.914040 
31.091950 
42.005989 
Means for Oneway Anova 
Level Number Mean 
Coated 27 11.7270 
Tubing 30 I 0.8507 
Std Error uses a pooled estimate of error variance 
ID N Mean(Ug/mL) 
Coated 30 11.727037 
Tubing 30 10.8506667 
Std Error 
0.14470 
0.13727 
65 
-· 
Tubing 
4 .3939 
55 
<.0001 
<.000 1 
1.0000 
Mean Square 
10.9 140 
0.5653 
Lower 95% 
11.437 
10.576 
Std. Deviation 
0.44454657 
0.94602228 
F Ratio 
19.3064 
Prob > F 
<.000 1 
Upper 95% 
12.017 
11.126 
3. lmL, 2mL, 4mL Reconstitution studies with different diluents 
A. 4mL Reconstitution with three different diluents 
Onewa Anal sis of Amount 
:::; 
E 
54-
53-
52-
51-
. 
I 
/mL B ID 
I 
.l,, 
. 
°' 2. 50 +-E3~~~::::::::::!E:::::::::: :___ -i---1 r :I. I r T I c 49-
::l 
0 48-~ 47-
46-
45-
- 11-
~L 
44-'-~~~~~--.r~~~~~~~r~~~~~--' 
.9 Nacl Recon 4ml H20 Recon 4ml 
1.8 Nacl Recon 4ml 
Oneway Anova 
Summary of Fit 
Rsquare 
Adj Rsquare 
Root Mean Square Error 
Mean of Response 
Observations (or Sum Wgts) 
Analysis of Variance 
Source DF 
ID 2 
Error 87 
C. Total 89 
Means for Oneway Anova 
Level 
.9 Nae! Recon 4mL 
1.8 NacL Recon 4mL 
H20 Recon 4mL 
ID 
0.24949 
0.232237 
1.508886 
49.78367 
90 
Sum of Squares 
65.84586 
198.07603 
263 .92189 
Number 
30 
30 
30 
Mean 
50.1027 
50.6347 
48.6137 
Std Error uses a pooled estimate of error variance 
ID 
.9 Nacl Recon 4mL 
1.8 NacL Recon 4mL 
H20 Recon 4mL 
N 
30 
30 
30 
Mean (Ug/mL) 
50.1026667 
50.6346667 
48.6136667 
66 
Mean Square 
32.9229 
2.2767 
Std Error 
0.27548 
0.27548 
0.27548 
F Ratio 
14.4606 
Lower 95% 
49.555 
50.087 
48.066 
Std. Dev. 
1.8262963 
1.240847 13 
1.39826613 
Prob> F 
<.000 1 
Upper 95% 
50.650 
51.182 
49 .1 61 
B. 2mL Reconstitution with three differenet diluents 
Onewa Anal sis of Amount U /rnL B ID 
125~~~~~~~~~~~~~~~~~~~~~~ 
120-
115-
95-
90-
85--'-~~~~~~-,...-,~~~~~~~,~~~~~~--' 
0.9 Nacl Recon 2ml H20 Recon 2ml 
1.8 Nacl Recon 2ml 
Oneway Anova 
Summary of Fit 
Rsquare 
Adj Rsquare 
Root Mean Square Error 
Mean of Response 
Observations (or Sum Wgts) 
Analysis of Variance 
Source OF 
ID 2 
Error 87 
C. Total 89 
ID 
0.058987 
0.037355 
4.881897 
102.9313 
90 
Sum of Squares 
129.9745 
2073.4641 
2203.4386 
Mean Square 
64.9873 
23.8329 
F Ratio 
2.7268 
Means for Oneway Anova 
Level 
0.9 NacL Recon 2mL 
1.8 NacL Recon 2mL 
H20 Recon 2mL 
Number 
30 
30 
30 
Mean 
104.476 
102.772 
101.546 
Std Error 
0.89131 
0.89131 
0.89131 
Lower95% 
102.70 
I 01.00 
99.77 
Std Error uses a pooled estimate of error variance 
ID 
0.9 NacL Recon 2mL 
1.8 NacL Recon 2mL 
H20 Recon 2mL 
N 
30 
30 
30 
Mean(U g/rnL) 
104.476333 
102.772 
101.545667 
67 
Std. Dev 
6.86423489 
1.4194059 
4.72930532 
Prob> F 
0.0710 
Upper 95% 
106.25 
104.54 
103.32 
c. 1 mL Reconstitution with three different diluents 
Onewa Anal sis of Amount U /mL B ID 
220.....-~~~~~~~~~~~~~~~~~~---, 
::J' 
215 
210 
.€ 205 
Ol 
:::> 
::: 200 
c: 
::> 
0 195 ~ 190 
185 
1 80-L-~~~~~~~~~~~~r--~~~~~~ 
0.9 Nacl Recon 1 ml H20 Recon 1 ml 
1.8 Nacl Recon 1 ml 
Oneway Anova 
Summary of Fit 
Rsquare 
Adj Rsquare 
Root Mean Square Error 
Mean of Response 
Observations (or Sum Wgts) 
Analysis of Variance 
Source DF 
ID 2 
Error 85 
C. Total 87 
Means for Oneway Anova 
Level 
0.9 Nacl Recon I mL 
1.8 NacL Recon I mL 
H20 Recon I mL 
ID 
0.084041 
0.062489 
7.609981 
202.6765 
88 
Sum of Squares 
451.6508 
4922.5038 
5374.1546 
Number 
28 
30 
30 
Mean 
205.959 
201.538 
200.752 
Mean Square 
225.825 
57.912 
Std Error 
1.4382 
1.3894 
1.3894 
Std Error uses a pooled estimate of error variance 
ID 
0.9 Nacl Recon lrnL 
1.8 NacL Recon 1 rnL 
H20 Recon 1 rnL 
N 
30 
30 
30 
Mean 
205.95857 1 
20 1.538 
200.751667 
68 
Std. Dev. 
6.98180212 
8.36 18734 1 
7.37812895 
F Ratio 
3.8995 
Lower 95% 
203.10 
198.78 
197.99 
Prob> F 
0.0240 
Upper 95% 
208.82 
204.30 
203.51 
4. Annealing vs. No Annealing full lyophilization cycle 
A) Full lvophiliazation cycle with annealing 
Onewa Anal sis of Mean Cone. U /mL B ID 
35 -
. 
30 
::J' 
E 
°' 
25 
:::> 
- l l 
_l -.. 
• T 
-
I 
I 
c..i 
I 
c . 
0 
~ 20 c - . 
ro 
(1) 
:2 
15 -
·"" ..I. 
10 --; : 
I I I I 
Coated Pre-Lyo Coated Pre-Lyo PPE Pre-Lyo Tubing Tubing 
ID 
Oneway Anova 
Summary of Fit 
Rsquare 0.960408 
Adj Rsquare 0.959292 
Root Mean Square Error 1.59899 
Mean of Response 21 .06707 
Observations (or Sum Wgts) 147 
Analysis of Variance 
Source OF Sum of Squares Mean Square F Ratio Prob > F 
ID 4 8806.9416 2201.74 861. 1397 <.0001 
Error 142 363.0612 2.56 
C. Total 146 9170.0028 
Means for Oneway Anova 
Level Number Mean Std Error Lower 95% Upper 95% 
Coated 30 12.1363 0.29193 11.559 12.713 
Pre-Lyo Coated 28 27.4707 0.30218 26.873 28.068 
Pre-Lyo PPE 29 28.2148 0.29692 27.628 28.802 
Pre-Lyo Tubing 30 26.7810 0.29193 26.204 27 .358 
Tubing 30 11 .3977 0.29193 10.821 11.975 
Std Error uses a pooled estimate of error variance 
ID N Mean(Ug/mL) Std Dev 
Coated 30 12.1363333 0.2688992 
Pre-Lyo Coated 30 27.4707143 3.05278613 
Pre-Lyo PPE 30 28.2148276 1.46510999 
Pre-Lyo Tubing 30 26.78 1 0.91070397 
Tubing 30 11 .3976667 0.93185645 
69 
A. Continued Full lyophiliazation cycle with annealing 
Onewa Anal sis of Mean Cone. U /mL B ID 
12.5 
~ 12 
...J 
E g 11 .5 
<.i 
c 
0 11 ~ 
c 
~ 10.5 
~ 
10 
9.5 
Type I Tubing- Untreated Type I+ Coated 
Oneway Anova 
Summary of Fit 
Rsquare 
Adj Rsquare 
Root Mean Square Error 
Mean of Response 
Observations (or Sum Wgts) 
t Test 
Type I Tubing- Untreated-Type I+ Coated 
Assuming equal variances 
Difference 
Std Err Dif 
Upper CL Dif 
Lower CL Dif 
Confidence 
I 
-1.0 -0.5 .0 
Analysis of Variance 
-0.7387 t Ratio 
0.1771 DF 
-0.3842 Prob > ltl 
-1.0931 Prob > t 
0.95 
.5 
Prob < t 
I 
1.0 
ID 
0.230783 
0.217521 
0.685807 
11.767 
60 
Source DF 
ID I 
Error 58 
C. Total 59 
Sum of Squares 
8.184427 
27.279233 
35.463660 
Means for Oneway Anova 
Level Number 
Type I Tubing- Untreated 30 
Type I+ Coated 30 
Std Error uses a pooled estimate of error variance 
Mean 
11 .3977 
12.1363 
70 
-4.1715 
58 
0.0001 
0.9999 
<.000 1 
Mean Square 
8.18443 
0.47033 
Std Error 
0.12521 
0.12521 
F Ratio 
17.4014 
Lower 95% 
11.147 
11 .886 
Prob> F 
0.0001 
Upper 95% 
11 .648 
12.387 
B. Full Cycle without annealing 
Onewa Anal sis of Mean Cone. U /mL B ID 
13 
::J' 12 
E 
Ci 
'.:) 
<..i 11 
c 
0 
~ 
c 10 
"' Q) 
:2 
9 
Type 1 Siliconized Tubing Type 1 Unsiliconized Tubing 
Oneway Anova- Summary of Fit 
Rsquare 
Adj Rsquare 
Root Mean Square Error 
Mean of Response 
Observations (or Sum Wgts) 
t Test 
ID 
0.638483 
0.630075 
0.89959 
11.494 
45 
Type I Siliconized Tubing-Type I Uns iliconized Tubing 
Assuming equal variances 
Difference 2.34250 T Ratio 
0.26880 OF 
2.88459 Prob > !ti 
1.8004 1 Prob > t 
8.714533 
Std Err Dif 
Upper CL Dif 
Lower CL Dif 
Confidence 
I 
-2 
,!, 
-1 0 
Analysis of Variance 
Source OF 
ID I 
Error 43 
C. Total 44 
Means for Oneway Anova 
Level 
Type I Siliconized Tubing 
Type I Unsilicon ized Tubing 
0.95 Prob < t 
I I I 
2 
Sum of Squares 
6 1.457830 
34.798250 
96.256080 
Number 
21 
24 
Std Error uses a pooled estimate of error variance 
ID 
Type 1 Siliconized Tubing 30 
Type 1 Unsiliconized Tubing 30 
Mean 
12.7433 
I 0.4008 
71 
43 
<.0001 
<.000 1 
1.0000 
Mean Square 
61.4578 
0.8093 
Std Error 
0.19631 
0.18363 
Mean (Ug) 
12.7433333 
10.4008333 
F Ratio Prob> F 
75.9431 <.0001 
Lower 95% Upper 95% 
12.347 13.139 
10.o3 l 10.771 
Std. Dev. 
0.43706216 
1.16054304 
c. Comparison of annealed and unannealed products 
Oneway Analysis of Mean (Cone. Ug/mL) By ID 
12 
11 .5 
::::J 11 
..§ 
Cl 
:;:) 
u 10.5 
c: 
0 
10 s 
c: 
~ 9.5 
:::? 
9 
8.5 
•. 
Type 1 Unsiliconized Tubing- Annealed Type 1 Unsiliconized Tubing- Not Annealed 
Oneway Anova- Summary of Fit 
Rsquare 
Adj Rsquare 
Root Mean Square Error 
Mean of Response 
Observations (or Sum Wgts) 
t Test 
0.1 90883 
0.175323 
1.039232 
10.95463 
54 
ID 
Type I Unsiliconized Tubing-Type I Unsiliconized Tubing- Annealed 
Assuming equal variances 
Difference 
Std Err Dif 
Upper CL Dif 
Lower CL Dif 
Confidence 
-1.0 -0.5 .0 
Analysis of Variance 
Source OF 
ID I 
Error 52 
C. Total 53 
-0.9968 t Ratio 
0.2846 OF 
-0.4257 Prob > !ti 
-1. 5679 Prob > t 
.5 
0.95 Prob < t 
I 
1.0 
Sum of Squares 
13.249023 
56.160120 
69.409143 
Means for Oneway Anova 
Level Number 
24 
30 
Type I Unsi liconized Tubing 
Type I Unsi liconized Tubing- Annealed 
Std Error uses a pooled estimate of error variance 
ID 
Type 1 Unsiliconized Tubing 
Type 1 Unsiliconized Tubing- Annealed 
-3.5025 I 
52 
0.0010 
0.9995 
0.0005 
Mean Square 
13.2490 
1.0800 
Mean Std Error 
I 0.4008 0.21213 
11.3977 0.18974 
N Mean 
24 10.4008 
30 11.3977 
72 
F Ratio Prob> F 
12.2676 0.0010 
Lower 95% Upper 95% 
9.975 10.827 
I 1.017 11.778 
Std. Dev 
1.16054304 
0.93185645 
Section 2: Vial Experiments 
A. Siliconized vs. Untreated vials- Concentration 
Onewa Anal sis of Mean Cone. U /mL B ID 
13 
:::;- 12 
. .§ 
Ol ---- i 
::::> 
u 11 I 
c 
0 
~ 
c 10 co 
Q) 
~ 
9 
Type 1 Siliconized Tubing Type 1 Unsiliconized Tubing 
Oneway Anova- Summary of Fit 
Rsquare 
Adj Rsquare 
Root Mean Square Error 
Mean of Response 
Observations (or Sum Wgts) 
t Test 
ID 
0.638483 
0.630075 
0.89959 
11.494 
45 
Type 1 Siliconized Tub ing-Type 1 Unsi liconized Tubing 
Assuming equal variances 
Difference 
Std Err Dif 
Upper CL Dif 
Lower CL Dif 
Confidence 
1 
-2 -1 0 
Analysis of Variance 
Source DF 
ID 1 
Error 43 
C. Total 44 
2.34250 t Ratio 
0.26880 DF 
2.88459 Prob > ltl 
1.8004 1 Prob > t 
0.95 Prob < t 
I I, 
2 
Sum of Squares 
61.457830 
34.798250 
96.256080 
Means for Oneway Anova 
Level Number Mean 
Type I Siliconized Tubing 21 12.7433 
Type I Unsil iconized Tubing 24 10.4008 
Std Error uses a pooled estimate of e1Tor variance 
8.714533 
43 
<.000 1 
<.0001 
1.0000 
Mean Square 
61.4578 
0.8093 
Std Error 
0.19631 
0.18363 
Lower 
95% 
12.347 
10.031 
ID N Mean (Ug) Std. Dev. 
F Ratio 
75.9431 
Type l Siliconized Tubing 30 12.7433333 0.43706216 
Type 1 Unsiliconized Tubing 30 10.4008333 1.16054304 
73 
Prob > F 
<.000 1 
Upper 95% 
13. 139 
10.771 
On~wa 
600 
• 
500 
I-
400 
E 300 I 3 
200 
100 
Control Type I Siliconized Tubing 
Pre-Lyo PPE Type I Unsiliconiz ' 
Oneway Anova 
Summary of Fit 
Rsquare 
Adj Rsquare 
Root Mean Square Error 
Mean of Response 
Observations (or Sum Wgts) 
Analysis of Variance 
Lot 
0.900712 
0.897402 
39.28993 
213.2786 
94 
Source DF Sum of Squares 
1260358.0 
138932.9 
1399290.8 
Mean Square 
Lot 3 
Error 90 
C. Total 93 
Means for Oneway Anova 
Level Number 
Coo tr~ 5 
Pre-Lyo PPE 30 
Type I Siliconized Tubing 30 
Type I Unsiliconized Tubing 29 
Std Error uses a pooled estimate of error variance 
Means and Std Deviations 
Mean 
16.133 
376.070 
162.061 
131 .848 
420119 
1544 
Std Error 
17.571 
7.173 
7.173 
7.296 
Level Numbe Mean Std Dev Std Err Mean 
r 
Control 5 16.133 2.1792 0.975 
Pre-Lyo PPE 30 376.070 58.1202 10.611 
Type I Siliconized Tubing 30 162.061 30.3346 5.538 
Type I Unsiliconized 29 131 .848 22.5734 4.192 
Tubing 
74 
F Ratio Prob> F 
272.1512 <.0001 
Lower95% Upper 95% 
-18.8 51 .04 
361.8 390.32 
147.8 176.31 
117.4 146.34 
Lower 95% Upper 95% 
13.43 18.84 
354.37 397.77 
150.73 173.39 
123.26 140.43 
B. Continued Siliconized vs. Untreated Vials- Potency by COBAS 
Onewa Anal sis of U/ml B Lot 
• 
200 • 
• 
180 • 
E 160 
3 • 140 I 
120 I I I 
• I 
100 
• 
• 
Type I Siliconized Tubing Type I Unsiliconized Tubin 
Oneway Anova 
Summary of Fit 
Lot 
Rsquare 
Adj Rsquare 
Root Mean Square Error 
Mean of Response 
Observations (or Sum Wgts) 
0.247365 
0.234161 
26.80439 
147.2105 
t Test 
Type I Siliconized Tubing-Type I Unsiliconized Tubing 
Assuming equal variances 
Difference 
Std Err Dif 
Upper CL Dif 
Lower CL Dif 
Confidence 
30.2125 t Ratio 
6.9803 DF 
44.1903 Prob>ltl 
16.2348 Prob > t 
0.95 Prob< t 
-40 -30 -20 -10 0 10 20 30 40 
Analysis of Variance 
Source DF 
Lot 1 
Error 57 
C. Total 58 
Means for Oneway Anova 
Sum of Squares 
13459.862 
40953.086 
54412.948 
Level Number 
Type I Siliconized Tubing 30 
Type I Unsiliconized Tubing 29 
Std Error uses a pooled estimate of error variance 
59 
4.328271 
57 
<.0001 
<.0001 
1.0000 
Mean Square 
13459.9 
718.5 
Mean 
162.061 
131.848 
Std Error 
4.8938 
4.9774 
75 
F Ratio 
18.7339 
Lower 95% 
152.26 
121 .88 
Prob> F 
<.0001 
Upper 95% 
171.86 
141 .82 
C. Type 1 + coated vials vs. untreated tubing vials 
Oneway Analysis of Mean (Cone. Ug/ml) By ID 
12.5 
~ 12 
...J 
E 
;gi 11 .5 ~E:=:__----=-----~=====--­
u 
c §. 11 
c 
IB 1 o.5 
~ 
10 
9.5 
Type I Tubing- Untreated Type I+ Coated 
Oneway Anova 
Summary of Fit 
Rsquare 
Adj Rsquare 
Root Mean Square Error 
Mean of Response 
Observations (or Sum Wgts) 
t Test 
ID 
0.230783 
0.217521 
0.685807 
11. 767 
60 
Type I Tubing- Untreated-Type I+ Coated 
Assuming equal variances 
Difference 
Std Err Dif 
Upper CL Dif 
Lower CL Dif 
Confidence 
I 
-1.0 -0.5 .0 
Analysis of Variance 
Source DF 
ID 1 
Error 58 
C. Total 59 
-0 .7387 t Ratio 
0.1771 OF 
-0 .3842 Prob> ltl 
-1 .0931 Prob> t 
0.95 Prob< t 
.5 
I 
1.0 
Sum of Squares 
8.184427 
27.279233 
35.463660 
Means for Oneway Anova 
Level Number Mean 
Type I Tubing- Untreated 30 11 .3977 
Type I+ Coated 30 12.1363 
Std Error uses a pooled estimate of error variance 
-4.1715 
58 
0.0001 
0.9999 
<.0001 
Mean Square 
8.18443 
0.47033 
Std Error 
0.12521 
0.12521 
76 
F Ratio Prob> F 
17.4014 0.0001 
Lower 95% Upper 95% 
11 .1 47 11.648 
11.886 12.387 
Section 3: Formulation Studies 
A. lX vs 2X formulation 
Onewa Anal sis of mean cone. u /ml B ID 
60 
I 
I 
50 _, T 
E 40 
Ci 
_, 
::l 
u 
c 
8 30 _, 
c 
ro J. 
Q) 
E I 
20 _, 
I 
10 
_._ ~- __._ 
_, -.- T 
T T T T T 
Coated 1 X NaCl 6ml PPE 1X PPE 2x Tubing 1X Nael 6ml 
Tubing 2X Na 
Oneway Anova 
Summary of Fit 
Rsquare 
Adj Rsquare 
Coated 2X NaCl 6ml 
Root Mean Square Error 
Mean of Response 
Observations (or Sum Wgts) 
Analysis of Variance 
ID 
0.996542 
0.996439 
0.914972 
20.90572 
173 
Source DF 
ID 5 
Error 167 
C. Total 172 
Sum of Squares 
40293.111 
139.808 
40432.919 
Mean Square 
8058.62 
0.84 
F Ratio 
9625 .975 
Means for Oneway Anova 
Level Number 
Coated IX NaCl 6ml 30 
Coated 2X NaCl 6ml 30 
PPEIX 30 
PPE 2x 29 
Tubing IX Nae I 6ml 24 
Tubing 2X Nacl 6ml 30 
Std Error uses a pooled estimate of error variance 
ID N 
Coated IX NaCl 6ml 30 
Coated 2X aCI 6ml 30 
PPE IX 30 
PPE 2x 30 
Tubing IX Nael 6m1 30 
Tubing 2X Nae) 6ml 30 
Mean Std Error Lower 95% 
11 .3520 
11 .5450 
26.5730 
52.5079 
10.7829 
11.7023 
Mean (Ug/mL) 
I I .352 
1 I.545 
26.573 
52.50793 I 
I0.7829I67 
I 1.7023333 
77 
0.16705 11.022 
0.16705 11.215 
0.16705 26.243 
0.16991 52.172 
0.18677 10.414 
0.16705 11.373 
Std. Dev. 
0.27873359 
0.26I2536I 
1.03509503 
1.74928226 
0.495251 I8 
0.67424381 
Prob> F 
<.0001 
Upper 95% 
11 .682 
11.875 
26.903 
52.843 
11.152 
12.032 
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